人民网北京12月16日电 （记者乔业琼）据厦门疾控微信公众号消息，免疫是人体与生俱来的健康 盾牌，而疫苗则是为这面盾牌特别锻造的"强化装备"。 那些疫苗"超能力" 天花疫苗：人类唯一彻底消灭的传染病，疫苗立下头功 脊髓灰质炎疫苗：让"小儿麻痹症"成为历史名词 HPV疫苗：目前唯一种能预防癌症的疫苗 疫苗的魔法：如何教会身体"记住"敌人？ 身体的免疫系统就像一支精锐部队，而疫苗的作用，就是给这支部队： 送上"敌人画像"（灭活/减毒疫苗） 展示"敌人武器模型"（重组蛋白疫苗） 提供"敌人作战手册"（mRNA疫苗） 通过这种方式，免疫系统在不经历真实感染风险的情况下，提前认识了敌人，并形成了长期"记 忆"。当真正的病原体入侵时，记忆免疫细胞便会迅速识别并消灭它们——这个过程甚至可能快到你感 觉不到自己曾被感染。 三是"群体免疫"是什么？ 关于疫苗的"灵魂三问" 一是为什么打了疫苗还会生病？ 疫苗不是"金钟罩"，而更像是"防弹衣"。它能显著降低重症和死亡风险，就像戴了头盔虽然可能还 会受伤，但能保住性命。 二是疫苗副作用可怕吗？ 常见的局部红肿、低热，其实是免疫系统正在"认真学习"的表现。严重不良反应的发生率，比许多 ...

Financial Data and Key Metrics Changes - The company reported an adjusted EBITDA of approximately $183 million for 2024, a significant improvement from a negative EBITDA in 2023 [20][22] - Net debt leverage decreased from about 9.9 times a year ago to approximately 1.9 times currently, indicating improved financial stability [21][22] - Cash position improved dramatically from about $70 million a year ago to approximately $270 million as of June 30, 2024 [22] Business Line Data and Key Metrics Changes - The Narcan business is highlighted as a key revenue driver, with ongoing efforts to increase accessibility and awareness [26][27] - The biodefense segment, including products for smallpox, anthrax, and botulism, is expected to see increased demand due to bipartisan support for funding [32][64] Market Data and Key Metrics Changes - The opioid overdose death toll decreased from around 100,000 in 2023 to about 80,000 in 2024, attributed in part to Narcan's increased accessibility [12][26] - There is a growing international focus on biodefense, with NATO increasing defense spending and European countries looking to establish their own strategic stockpiles [15][16][32] Company Strategy and Development Direction - The company is focused on a multi-year turnaround strategy, emphasizing stabilization, operational efficiency, and debt reduction [20][22] - Future growth opportunities are being explored through organic product development and potential acquisitions in the biodefense sector [52][53] - The company is investing in international growth programs to expand its market presence and support global health initiatives [33][61] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of collaboration with the U.S. government and allied countries to address public health threats [10][11] - The company is optimistic about future growth, projecting a compound annual growth rate over a three to five-year timeframe [65][66] Other Important Information - The company has established a partnership with Swiss Rockets to develop next-generation vaccines, indicating a commitment to innovation in response to emerging health threats [41][42] - The company is actively working to enhance its customer focus and streamline operations to better serve first responders and government contracts [46][52] Q&A Session Summary Question: How is the company positioned to acquire assets in a consolidating industry? - The company believes it is well-positioned due to its knowledge of customer needs and its expertise in product development and commercialization [60][61] Question: What is the long-term value proposition for investors? - The company offers durable, sustainable product revenue, particularly in biodefense, with expectations for organic growth and strategic acquisitions [64][65]